ADA 2026 Opens in New Orleans: Retatrutide TRIUMPH-1 Full Data, Survodutide SYNCHRONIZE-1 Confirmation, CagriSema REIMAGINE 1–3 Symposium, and Zenagamtide Phase 2 — June 5, 2026 Peptide Research Update

ADA 2026 Begins: The Highest-Density Pipeline Event of the Year

The American Diabetes Association's 86th Scientific Sessions opened today in New Orleans (June 5–8, 2026), and the obesity-metabolic pipeline has delivered what may be the most consequential four-day data disclosure in the history of the GLP-1 era. For the first time, three late-stage compounds that have produced best-in-class weight loss signals are presenting full Phase 3 data at the same meeting: Eli Lilly's retatrutide (TRIUMPH-1 and TRIUMPH-4), Boehringer Ingelheim's survodutide (SYNCHRONIZE-1), and Novo Nordisk's CagriSema (REIMAGINE 1–3). Alongside these pivotal readouts, Novo Nordisk is also presenting Phase 2 data for zenagamtide — a new unimolecular GLP-1/amylin co-agonist that is the company's next-generation successor to the CagriSema combination strategy.

Retatrutide TRIUMPH-1: Full 80-Week Data Confirms 28.3% Weight Loss, Dysesthesia Signal Quantified

Eli Lilly's full TRIUMPH-1 Phase 3 data — the registrational trial for retatrutide's planned Q4 2026 NDA submission — confirm the topline results announced May 21: adults with obesity or overweight (without T2D) on the 12 mg once-weekly dose lost a mean 28.3% of body weight at 80 weeks, versus 2.8% on placebo. Participants on the 9 mg dose lost 25.9%, and the 4 mg dose delivered 19.0%. In the BMI ≥35 subgroup extended to 104 weeks, weight loss reached 30.3%, or approximately 85 lbs. The 12 mg group showed statistically significant improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein across all dose groups at 80 weeks. The full data also provide the most detailed picture yet of the dysesthesia safety signal: abnormal skin sensation (burning, tingling, altered touch sensitivity) was reported in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose, versus 0.7% on placebo — substantially higher than was visible in earlier trials. Most events were mild and rarely led to discontinuation, but the frequency at the 12 mg dose is high enough that it will be a differentiating factor in eventual prescribing decisions compared to other agents in the class. Discontinuation due to adverse events occurred in 18.2% of the 12 mg group. TRANSCEND-T2D-1 full data are also being presented, showing A1C reductions of up to 2.0% and weight loss of up to 16.8% at 40 weeks in T2D patients — the first T2D indication dataset for a triple agonist in pivotal Phase 3.

Survodutide SYNCHRONIZE-1: Full Data Confirms 16.6% Weight Loss With Favorable Body Composition

Boehringer Ingelheim and Zealand Pharma's full SYNCHRONIZE-1 data, presented at ADA 2026, confirm and expand on the April 2026 topline announcement: adults with obesity or overweight (without T2D) on survodutide — a dual GLP-1/glucagon receptor agonist — achieved 16.6% mean weight loss at 76 weeks versus 3.2% on placebo (p<0.0001), with 85.1% reaching ≥5% weight reduction versus 38.8% on placebo. The complete dataset introduces a particularly important differentiating detail: body composition analysis indicates that weight loss with survodutide was driven predominantly by fat mass, with lean mass comprising only a small proportion of total weight reduction — a profile consistent with the glucagon receptor component promoting hepatic fat oxidation and energy expenditure rather than catabolism. This body composition characterization strengthens survodutide's positioning for MASH (metabolic dysfunction-associated steatohepatitis), where hepatic fat reduction is the primary target. The NDA filed in February 2026 under Priority Review is targeting an FDA decision in Q3 2026. Survodutide has FDA Breakthrough Therapy designation for MASH, and separate SYNCHRONIZE-MASLD data are also being presented at ADA 2026.

CagriSema REIMAGINE 1–3: The First Amylin-GLP-1 T2D Program Presented in Full

Novo Nordisk is hosting a dedicated symposium at ADA 2026 presenting REIMAGINE 1, 2, and 3 — the Phase 3 CagriSema program in type 2 diabetes. REIMAGINE 2 (n=2,728, 68 weeks) established CagriSema 2.4 mg/2.4 mg as superior to semaglutide 2.4 mg alone, with a 1.91% HbA1c reduction and 14.2% weight loss, using the efficacy estimand. The treatment-regimen estimand showed 1.80% HbA1c reduction and 12.9% weight loss, both still superior to semaglutide. The ADA symposium provides the first presentation of REIMAGINE 1 (monotherapy and active comparator arms) and REIMAGINE 3 (CagriSema as add-on to basal insulin), completing the picture of CagriSema's T2D evidence base. Novo Nordisk has stated it will approach regulatory authorities to discuss the T2D regulatory pathway following REIMAGINE 1 and REDEFINE 3 results — meaning CagriSema could ultimately seek approval in both obesity (NDA filed December 2025, decision anticipated October 2026) and type 2 diabetes as separate indications. The first amylin-GLP-1 combination to demonstrate superiority to GLP-1 alone in a pivotal T2D trial is a meaningful clinical milestone.

Zenagamtide: Novo Nordisk's Next-Generation Single-Molecule GLP-1/Amylin Agonist Shows Up to 24.3% Weight Loss

The newest compound from Novo Nordisk's obesity pipeline — zenagamtide (NN9487) — is being presented at ADA 2026 with Phase 2 data that represent the highest weight loss the company has yet reported for a single investigational molecule. Zenagamtide is a unimolecular GLP-1 and amylin receptor co-agonist, engineered as a single peptide that activates both the GLP-1 receptor and the amylin receptor simultaneously — conceptually the same dual-pathway mechanism as CagriSema, but encoded in one molecule rather than two combined. The Phase 2 subcutaneous data in obesity showed up to 24.3% weight loss. In the T2D Phase 2 trial (36 weeks), subcutaneous zenagamtide delivered 14.5% weight loss and a 1.8% HbA1c reduction, with 89% of participants reaching HbA1c below 7.0%. Oral zenagamtide Phase 2 data showed 7.6% placebo-adjusted weight loss in T2D and approximately 13% in obesity — consistent with the class discount expected for oral administration relative to injectable. Crucially, both subcutaneous and oral formulations were still on an ascending curve at trial end, suggesting the plateau has not yet been reached. The Phase 3 AMAZE program has been initiated, with AMAZE 1 (obesity) and AMAZE 2 (T2D + obesity), both 84-week trials versus placebo. Zenagamtide is not yet approved anywhere and is available only through clinical trials.

What ADA 2026 Means for the Pipeline Landscape

ADA 2026 is functionally the moment when the next wave of obesity medicines transitions from 'promising' to 'documented.' Retatrutide's pivotal data now support a Q4 2026 NDA filing that, if approved, would offer the first triple agonist — and the highest-efficacy approved weight-loss therapy by a significant margin — to the US market. Survodutide's NDA is already under Priority Review, with a Q3 2026 FDA decision possible. CagriSema's NDA is under review for an October 2026 decision. Against this backdrop, zenagamtide's Phase 2 data make it the most important next-generation molecule in Novo Nordisk's pipeline, positioned to enter pivotal trials as the company's first-mover advantage on amylin-GLP-1 begins to face competition. The open questions from ADA 2026 are substantial: Can survodutide secure approval before retatrutide files? Will CagriSema's October 2026 FDA decision come before or after zenagamtide reaches Phase 3 readout? And does the dysesthesia signal in retatrutide's TRIUMPH-4 data create a prescribing friction point that benefits competitors? None of these are settled this week — but the data to answer them now exist. As with all content on this site, these are research summaries only; none of the compounds discussed are approved for clinical use, and nothing here constitutes medical advice.

Citations

1. [1] Source
2. [2] Source
3. [3] Source
4. [4] Source
5. [5] Source
6. [6] Source
7. [7] Source
8. [8] Source

Related Articles

research-summaries

Petrelintide and the Amylin Moment: Zealand and Roche's Phase 2 Win on Tolerability Heads to ADA 2026 — June 1, 2026 Peptide Research Update

Zealand Pharma and Roche's amylin analog petrelintide delivered up to 10.7% mean weight loss in the Phase 2 ZUPREME-1 trial with GI side effects comparable to placebo - a tolerability-first profile heading to ADA 2026 as the amylin class matures into the next pillar of obesity care.

PepTracker Pro Research Team

June 1, 2026 8 min read min read

petrelintideZP8396amylin

Read

research-summaries

Enicepatide (CT-388) Posts ~22.5% Weight Loss in Phase 2 and Heads to ADA 2026: Roche's Signal-Biased GLP-1/GIP Agonist - June 4, 2026 Peptide Research Update

Roche and Genentech's investigational dual GLP-1/GIP receptor agonist enicepatide (CT-388) delivered up to ~22.5% placebo-adjusted weight loss at 48 weeks in its Phase 2 trial - among the largest incretin results to date - and presents late-breaking data at ADA 2026 as it advances to Phase 3 and toward a fixed-dose combination with petrelintide.

PepTracker Pro Research Team

June 4, 2026 8 min read min read

enicepatideCT-388RO7795068

Read